Table 2 Open in new tab Univariate and...

Variable	PFS (n = 38)
Age (years)
<68	1
≥68	0.769 (0.363–1.631)	0.4935
Sex
Male	1
Female	1.370 (0.577–3.252)	0.4753
Performance status
0, 1	1
≥2	1.047 (0.313–3.498)	0.9411
IMDC risk classification
Favorable	1
Intermediate	0.997 (0.331–3.003)	0.9956
Poor	0.965 (0.276–3.380)	0.9560
Liver metastasis
No	1
Yes	0.910 (0.343–2.415)	0.8497
Bone metastasis
No	1
Yes	0.999 (0.434–2.298)	0.9973
Number of prior regimens
1	1
≥2	0.683 (0.322–1.449)	0.3210
Alb (g/dl)
≥3.5	1
<3.5	1.047 (0.491–2.233)	0.9053
CRP (mg/dl)
<1.0	1
≥1.0	1.251 (0.592–2.640)	0.5574
NLR
<3.0	1		1
≥3.0	2.064 (0.975–4.366)	0.0581	1.623 (0.737–3.575)	0.2292
ALC
≥1300/μl	1		1
<1300/μl	2.708 (1.226–5.980)	0.0137	2.332 (1.012–5.375)	0.0468
MLR
<0.3	1
≥0.3	1.731 (0.806–3.715)	0.1593
PLR
<160	1
≥160	1.705 (0.795–3.658)	0.1706

Variable

PFS (n = 38)

Univariate analysis

Multivariate analysis

P value

Age (years)

<68

≥68

0.769 (0.363–1.631)

0.4935

Sex

Male

Female

1.370 (0.577–3.252)

0.4753

Performance status

0, 1

≥2

1.047 (0.313–3.498)

0.9411

IMDC risk classification

Favorable

Intermediate

0.997 (0.331–3.003)

0.9956

Poor

0.965 (0.276–3.380)

0.9560

Liver metastasis

Yes

0.910 (0.343–2.415)

0.8497

Bone metastasis

Yes

0.999 (0.434–2.298)

0.9973

Number of prior regimens

≥2

0.683 (0.322–1.449)

0.3210

Alb (g/dl)

≥3.5

<3.5

1.047 (0.491–2.233)

0.9053

CRP (mg/dl)

<1.0

≥1.0

1.251 (0.592–2.640)

0.5574

NLR

<3.0

≥3.0

2.064 (0.975–4.366)

0.0581

1.623 (0.737–3.575)

0.2292

ALC

≥1300/μl

<1300/μl

2.708 (1.226–5.980)

0.0137

2.332 (1.012–5.375)

0.0468

MLR

<0.3

≥0.3

1.731 (0.806–3.715)

0.1593

PLR

<160

≥160

1.705 (0.795–3.658)

0.1706

Variable	PFS (n = 38)
Age (years)
<68	1
≥68	0.769 (0.363–1.631)	0.4935
Sex
Male	1
Female	1.370 (0.577–3.252)	0.4753
Performance status
0, 1	1
≥2	1.047 (0.313–3.498)	0.9411
IMDC risk classification
Favorable	1
Intermediate	0.997 (0.331–3.003)	0.9956
Poor	0.965 (0.276–3.380)	0.9560
Liver metastasis
No	1
Yes	0.910 (0.343–2.415)	0.8497
Bone metastasis
No	1
Yes	0.999 (0.434–2.298)	0.9973
Number of prior regimens
1	1
≥2	0.683 (0.322–1.449)	0.3210
Alb (g/dl)
≥3.5	1
<3.5	1.047 (0.491–2.233)	0.9053
CRP (mg/dl)
<1.0	1
≥1.0	1.251 (0.592–2.640)	0.5574
NLR
<3.0	1		1
≥3.0	2.064 (0.975–4.366)	0.0581	1.623 (0.737–3.575)	0.2292
ALC
≥1300/μl	1		1
<1300/μl	2.708 (1.226–5.980)	0.0137	2.332 (1.012–5.375)	0.0468
MLR
<0.3	1
≥0.3	1.731 (0.806–3.715)	0.1593
PLR
<160	1
≥160	1.705 (0.795–3.658)	0.1706

Table 2

Open in new tab

Univariate and multivariate analyses of progression-free survival (PFS) in patients with metastatic renal cell carcinoma (RCC) who were treated with nivolumab

Variable	PFS (n = 38)
	Univariate analysis		Multivariate analysis
	HR	P value	HR	P value
Age (years)
<68	1
≥68	0.769 (0.363–1.631)	0.4935
Sex
Male	1
Female	1.370 (0.577–3.252)	0.4753
Performance status
0, 1	1
≥2	1.047 (0.313–3.498)	0.9411
IMDC risk classification
Favorable	1
Intermediate	0.997 (0.331–3.003)	0.9956
Poor	0.965 (0.276–3.380)	0.9560
Liver metastasis
No	1
Yes	0.910 (0.343–2.415)	0.8497
Bone metastasis
No	1
Yes	0.999 (0.434–2.298)	0.9973
Number of prior regimens
1	1
≥2	0.683 (0.322–1.449)	0.3210
Alb (g/dl)
≥3.5	1
<3.5	1.047 (0.491–2.233)	0.9053
CRP (mg/dl)
<1.0	1
≥1.0	1.251 (0.592–2.640)	0.5574
NLR
<3.0	1		1
≥3.0	2.064 (0.975–4.366)	0.0581	1.623 (0.737–3.575)	0.2292
ALC
≥1300/μl	1		1
<1300/μl	2.708 (1.226–5.980)	0.0137	2.332 (1.012–5.375)	0.0468
MLR
<0.3	1
≥0.3	1.731 (0.806–3.715)	0.1593
PLR
<160	1
≥160	1.705 (0.795–3.658)	0.1706

Variable	PFS (n = 38)
	Univariate analysis		Multivariate analysis
	HR	P value	HR	P value
Age (years)
<68	1
≥68	0.769 (0.363–1.631)	0.4935
Sex
Male	1
Female	1.370 (0.577–3.252)	0.4753
Performance status
0, 1	1
≥2	1.047 (0.313–3.498)	0.9411
IMDC risk classification
Favorable	1
Intermediate	0.997 (0.331–3.003)	0.9956
Poor	0.965 (0.276–3.380)	0.9560
Liver metastasis
No	1
Yes	0.910 (0.343–2.415)	0.8497
Bone metastasis
No	1
Yes	0.999 (0.434–2.298)	0.9973
Number of prior regimens
1	1
≥2	0.683 (0.322–1.449)	0.3210
Alb (g/dl)
≥3.5	1
<3.5	1.047 (0.491–2.233)	0.9053
CRP (mg/dl)
<1.0	1
≥1.0	1.251 (0.592–2.640)	0.5574
NLR
<3.0	1		1
≥3.0	2.064 (0.975–4.366)	0.0581	1.623 (0.737–3.575)	0.2292
ALC
≥1300/μl	1		1
<1300/μl	2.708 (1.226–5.980)	0.0137	2.332 (1.012–5.375)	0.0468
MLR
<0.3	1
≥0.3	1.731 (0.806–3.715)	0.1593
PLR
<160	1
≥160	1.705 (0.795–3.658)	0.1706

HR, hazard ratio; Alb, albumin; CRP, C-reactive protein; NLR, neutrophil–lymphocyte ratio; ALC, absolute lymphocyte count; MLR, monocyte–lymphocyte ratio; PLR, platelet–lymphocyte ratio.

This Feature Is Available To Subscribers Only